ArticleLife (Basel, Switzerland)2025
Pancreatic Injury in Severe SARS-CoV-2 Infection: A Retrospective Study Across Three Pandemic Waves.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) has emerged as a notable complication in patients with COVID-19, yet the interplay between viral infection, systemic inflammation, and pancreatic injury remains incompletely understood. This study aimed to evaluatethe characteristics and risk factors of APin patients with severe COVID-19 pneumonia. We conducted a retrospective, single-center analysis of 405 hospitalized COVID-19 patients with and without AP. Laboratory markers, including CRP, ESR, fibrinogen, LDH, D-dimers, WBC, neutrophils, serum potassium, and serum glucose, alongside imaging and clinical parameters, were analyzed for associations with AP occurrence. Our results indicate that elevated inflammatory and coagulation markers, leukocytosis with neutrophilia, hyperglycemia, hypokalemia, and more severe pulmonary involvement were significantly associated with AP in COVID-19. LDH and inflammatory markers demonstrated particularly strong predictive value, while D-dimers and lung injury severity also contributed to risk stratification. These findings suggest that systemic inflammation, endothelial dysfunction, immunothrombosis, and metabolic impairments converge to increase pancreatic vulnerability in COVID-19 patients. Early recognition of these risk factors may guide monitoring and therapeutic interventions, although prospective validation is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.